UCSF at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
UCSF brings 4 presentations to ASH 2026 in New Orleans. Its program centres on regulatory T cells as therapy, including engineered CAR-Tregs that restore immune tolerance in autoimmune disease. It also weighs bispecific antibodies against CAR T for early myeloma relapse and looks at the care of patients in prison.
| Organization | ASH 2026 Attendance |
|---|---|
UCSF San Francisco, CA | |
University of California's health sciences campus in San Francisco, focused on medicine, biomedical research and graduate health education. | Symposium Fri Dec 11 7:00pm–10:00pm Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care Where bispecific antibodies fit in diffuse large B-cell lymphoma, weighed against CAR-T by patient fitness, access, and T-cell health. Symposium Fri Dec 11 3:00pm–6:00pm Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing. Talk Promoting the Peacekeepers: Treg Adoptive Therapies to Re-Establish Tolerance Regulatory T cells redirected with chimeric antigen receptors to restore immune tolerance in rheumatoid arthritis, from lab studies to clinical findings. Talk Bispecific Antibodies OR CAR-T in Early Relapse for Multiple Myeloma Comparing CAR-T cells with off-the-shelf bispecific antibodies for early-relapse myeloma, weighing trial evidence, risks, and the best treatment order. |
Instantly find 20 buyers from UCSF
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction